📅 PUBMED DAILY TRIAGE — 2026-08-11

Window: 2026-08-10T00:00:00Z → 2026-08-11T23:59:59Z (CRDT) Topics scanned: 10 | Candidates evaluated: ~97 across all topics | Articles retained: 25 High priority: 10 | Standard: 15 | Low/archive: 0 | Unsolicited finds: 1 Run status: PARTIAL_SUCCESS (T4, T5, T6, T7, T8, Sentinel did not reach full candidate cap — see Run Notes)

🔴🟠 HIGH PRIORITY (score ≥ 8 or EARLY_CANCER_DETECTION / NOVEL_TREATMENT flag) — Best Finds by Topic

🩸 Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

[42575986] · Decade-long persistence of CD19 CAR T cells in B cell lymphomas · 9/10 · 🟠 NOVEL_TREATMENT Nature Medicine | Paruzzo L … Schuster SJ, Ruella M

First 10-year persistence data for 4-1BB CAR T cells in NHL (n=38): 5/8 long-term responders retained detectable CAR transgene past year 5; dominant CD4−CD8− effector-memory phenotype with oligoclonal PACS1-integrated clone persisting 9.3 years. Landmark finding for understanding durable CAR T remissions.

[42575099] · Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment · 8/10 · 🟠 NOVEL_TREATMENT Cancer Cell | Kehl N … Friedrich MJ

Identifies a latent but activatable non-exhausted effector T cell compartment in MM and AML bone marrow, plus TFiT transcriptional classifier that predicts immunotherapy (not chemotherapy) response across independent cohorts. Novel immunotherapy target framework for hematologic malignancies.

🔬 Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

[42574031] · Liquid Biopsies for Cancer: A Translational Science Review · 8/10 · 🔴 EARLY_CANCER_DETECTION JAMA | Mezzanotte-Sharpe J, Piemonte K, Park BH

Comprehensive JAMA review synthesizing ctDNA clinical utility: molecular relapse detected ~8.7 months earlier than imaging in CRC; HR for DFS 20.69 (95% CI 9.63–44.43) with high ctDNA in 1,725-patient urothelial meta-analysis. Essential reference for ctDNA pipeline integration.

[42574466] · An alignment-free strategy for circulating tumor DNA detection and tumor fraction estimation from whole-genome sequencing data · 7/10 · 🔴 EARLY_CANCER_DETECTION PLoS Computational Biology | Oroperv C … Besenbacher S, IMPROVE-consortia

ctDNAmer, an alignment-free k-mer ctDNA detection tool, detected recurrence in 77% of stage III CRC patients 8 months before imaging (n=90, 3-yr follow-up; Pearson r=0.897 with allele-frequency TF estimates). Novel ctDNA detection method overcoming alignment-dependent limitations.

[42573798] · Cerebrospinal fluid cell-free DNA sequencing in pediatric CNS tumors: towards liquid molecular neuropathology · 7/10 · 🔴 EARLY_CANCER_DETECTION Acta Neuropathologica | Gehin W, Merlin MS, Harle A, Merlin JL

Reviews CSF-derived cfDNA sequencing as a CNS-specific liquid biopsy platform addressing the blood-brain barrier limitation of blood ctDNA, with potential for methylation profiling and molecular monitoring of pediatric medulloblastoma, DIPG, and glioma. Emerging field with critical gap-filling applications.

[42573888] · Circulating microRNAs: a new era in early detection of oral squamous cell carcinoma (OSCC) — a systematic review and meta-analysis · 7/10 · 🔴 EARLY_CANCER_DETECTION Journal of the Egyptian National Cancer Institute | Pathan RM … Bade PGT

Systematic review and meta-analysis pooling diagnostic accuracy of circulating miRNA panels for OSCC early detection; supports feasibility of non-invasive blood-based miRNA profiling for high-risk populations with call for panel standardization. Pooled evidence base for an underserved early-detection domain.

🤖 AI/ML in Clinical Diagnostics and Imaging

[42576006] · AI-based multimodal integration of genomics and electronic health records · 8/10 · ⬜ NONE Nature Reviews Genetics | Venkatesh R, Ritchie MD

Nature Reviews Genetics review of AI/ML architectures (deep learning, transformers) integrating multi-omics and longitudinal EHR data, covering EHR-linked biobank development, disease subtyping, risk prediction, and clinical implementation challenges including equity and generalizability. Essential reference for the AI/ML diagnostics watchlist.

🧬 Precision Oncology and Genomic Medicine

[42576026] · Prevalence and chronology of colibactin-associated mutational processes and their microbiome spectra in Japanese colorectal cancer · 8/10 · 🔴 EARLY_CANCER_DETECTION Nature Genetics | Shiba S, Yachida S … Shibata T

Multi-omic WGS + transcriptomics + fecal metagenomics: colibactin mutational signatures (SBS88/ID18) are early clonal events in 44.8% of non-hypermutated Japanese CRC, with higher prevalence in post-1960s birth cohorts; AI-based microbiome analysis defines 4 CRC subtypes. Modifiable CRC risk factor with prevention and subtyping implications.

💉 Novel Therapeutics: Immunotherapy, CAR-T, Targeted Therapy

[42575473] · Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced ESCC: 5-year follow-up results from CheckMate 648 · 8/10 · 🟠 NOVEL_TREATMENT Annals of Oncology | Kato K … Chau I

Phase III 5-year update (n=970): both nivolumab+chemo (HR 0.62) and nivolumab+ipilimumab (HR 0.62) maintained OS benefit vs. chemo in PD-L1 ≥1% ESCC, no new safety signals. Most mature OS evidence confirming durable SOC immunotherapy benefit for ESCC.

🧬 Rare Diseases with High Unmet Need

[42573163] · A Randomized First-in-human Study of a Novel Growth Hormone Receptor Peptide Antagonist ALXN2420 in Healthy Subjects · 8/10 · 🟠 NOVEL_TREATMENT European Journal of Endocrinology | Allas S … van der Lely AJ

First randomized FIH study of ALXN2420, a novel peptide GH receptor antagonist for acromegaly (new mechanistic class vs. pegvisomant), demonstrating acceptable safety/tolerability with dose-dependent IGF-1 suppression. New therapeutic class entering clinical development for a rare disease with limited options.

🟢⚪ STANDARD (5–7) — Top by Topic

🩸 Hematologic Malignancies

• [42575085] · Beyond BCL-2: What drives venetoclax resistance in AML? · 7/10 · Cancer Cell — Reviews BCL-2-independent resistance (BAX mutations, mitochondrial remodeling, metabolic adaptations). Highly relevant to SOC venetoclax+azacitidine.
• [42575953] · The FOLR2-IRF2BP2 axis mediates erythropoiesis impairment by excess folic acid in MDS · 7/10 · Leukemia — Novel FOLR2 transcription factor axis impairing erythroid differentiation; IRF2BP2 is a new prognostic marker and therapeutic target in MDS.
• [42574951] · Stemness-driven INTS7 overexpression links metabolic comorbidity to chemoresistance in AML with type 2 diabetes · 6/10 · Leukemia Research — Mechanistic link between T2D comorbidity and AML chemoresistance via INTS7; relevant to the growing AML+T2D patient subgroup.

💊 Cardiovascular-Metabolic (GLP-1, SGLT2, Cardiometabolic Risk)

• [42575714] · Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis · 7/10 · Diabetes, Obesity and Metabolism — Real-world 6-month data confirming persistence-dependent tirzepatide benefit for obesity.
• [42575845] · AI Patient Support and 6-Month Medication Adherence in a Digital Obesity Program · 5/10 · Diabetes, Obesity and Metabolism — AI-driven digital support improves GLP-1 adherence in obesity digital programs.

💉 Novel Therapeutics

• [42575976] · Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy · 6/10 · Nature Nanotechnology — Pre-clinical (mouse only): oral nano-emulsion of 3,4-dihydroxybenzoic acid enhances CD8+ T cell stemness and anti-PD-1 synergy.
• [42575882] · CAR T cell therapy beyond cancer: current status, challenges and future prospects · 6/10 · Signal Transduction and Targeted Therapy — Comprehensive review of CAR T for autoimmune and fibrotic indications.
• [42576016] · Ferroptosis in T cells: mechanisms, biology and translational opportunities · 6/10 · Nature Reviews Immunology — Ferroptosis suppression as CAR T persistence strategy; translational opportunities in immunotherapy and autoimmunity.

🤖 AI/ML in Clinical Diagnostics

• [42575955] · Multiparametric MRI radiomics for noninvasive risk stratification of pediatric neuroblastoma: a pilot study · 6/10 · Scientific Reports — Pilot MRI radiomics study; moderate performance for non-invasive neuroblastoma risk stratification.

🦠 Rare Diseases

• [42573089] · Diagnostic delay in infants with very early-onset rare and ultra-rare genetic epilepsies · 7/10 · Dev Med Child Neurol — Documents substantial delays from seizure onset to genetic confirmation; case for rapid WGS pathways in neonatal epilepsy.
• [42573821] · Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review · 6/10 · Calcified Tissue International — TIO burden including multi-year diagnostic delays; burosumab as emerging non-surgical option.

🧓 Aging, Longevity, Population Health

• [42574711] · Relationship Between Cardiometabolic Index and Incident Frailty in Middle-Aged and Older Adults · 5/10 · Inquiry — CMI predicts incident frailty; cardiometabolic health as modifiable frailty prevention lever.
• [42575886] · Youthfulness of marrow Adipoq+ cells maintained by Cbfβ facilitates stem cell-based bone repair · 4/10 · Bone Research — Mouse study; Cbfβ decline with aging impairs marrow progenitor function; bone repair rejuvenation proof-of-concept.

🔵 CBC-Based Diagnostics and ML in Hematology

• [42572752] · Integrating Complete Blood Count Parameters with Demographic Characteristics for Obstructive Sleep Apnea Prediction in Chinese Adults: A Machine Learning Approach · 5/10 · Nature and Science of Sleep — Only T2-matched article today; CBC+ML for OSA prediction, not core hematologic diagnostics.

💡 UNSOLICITED FINDS

[42575581] · Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve · 7/10 · 🟢 NEAR_TERM_IMPLEMENTABLE JACC: Cardiovascular Interventions | Tanigaki T … Matsuo H

Multicenter RCT: angiography-derived FFR guided PCI decisions with clinical outcomes non-inferior to invasive wire-based FFR measurement. Practice-changing potential in interventional cardiology; sentinel find outside core watchlist.

📊 TODAY'S BREAKDOWN

By Pipeline Priority

By Research Category

By Evidence Maturity

By Watchlist Topic (reviewed / retained / highest score)

⚠️ Topics with incomplete 15-candidate review — see Run Notes.

Topics with zero HIGH articles today

• Cardiovascular-Metabolic (best: 42575714 score 7)
• CBC/ML Hematology (best: 42572752 score 5; only 1 result in window)
• Aging/Longevity/Population Health (best: 42574711 score 5)

By Source Type

• Peer-reviewed: 25 | Preprints: 0

🔧 RUN NOTES

PARTIAL_SUCCESS reasons:

• Topics T4 (AI/ML, 82 raw hits), T5 (Precision oncology, 16 hits), T6 (Novel therapeutics, 53 hits), T7 (Cardiovascular, 35 hits), T8 (Aging, 26 hits), and Sentinel (15 hits) did not achieve full candidate review due to API response size constraints per call. PMIDs reviewed: 5–7 per incomplete topic.
• Topics with complete coverage: T2 (1/1), T3 (10/10), T1 (~13/15 with 2 excluded), T9 (6/6).
• Missing candidate PMIDs for incomplete topics are logged in run_metadata.search_logs[*].missing_pmids.

Window expansion: Not triggered (all topics had at least 1 result in 24-hour window).

T2 note: CBC/ML hematology returned 1 result only (42572752 — OSA prediction). No fallback query needed per rules (result count > 0).

T8 note: humans[MeSH] filter applied per task spec. Of 5 reviewed candidates, 3 were off-topic (German-language clinical reviews, resting-state EEG reliability); only 2 T8-relevant articles retained.

Attempt: 2 of 3. Attempt files written to reports/pubmed/run-logs/; pending validator promotion to final paths.

Attempt 2 repairs (vs Attempt 1):

• Fixed per_topic_stats.hematologic_malignancies: PMID 42576077 moved to missing_pmids; candidates_reviewed corrected to 14 (from 13).
• Fixed search_logs.hematologic_malignancies: PMID 42576077 added to missing_pmids list.
• Fixed search_logs.precision_oncology_genomic_medicine: PMID 42573798 added to missing_pmids list.
• Fixed species_model enum values for PMIDs 42575099, 42575953, 42574951 ("human; mouse" → "mixed") and 42575976, 42575886 ("mouse" → "animal").